Can a Brain-Bleed drug protect memory after surgery?
NCT ID NCT05560373
First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time
Summary
This study tests whether huperzine A, an injected drug, can help prevent or reduce memory and thinking problems that often follow surgery for a bleeding brain aneurysm. Adults aged 18-70 who had an aneurysm bleed and underwent endovascular or surgical treatment will receive either huperzine A or standard care. Researchers will compare cognitive function and mood over time to see if the drug offers any benefit.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Huperzine A injection
- What this could lead to
- If effective, huperzine A could offer a way to reduce long-term memory and thinking problems after brain aneurysm surgery.
- What could go wrong
- This is a small pilot study, so results may not apply broadly. The drug may not improve cognition and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-70; * The patients were proved to be aneurysmal subarachnoid hemorrhage by imaging examination (head CT, CT angiography (CTA), whole brain angiography (DSA)); * Hunt Hess was graded I-III at admission; * The patients were treated with endovascular therapy or craniotomy and clipping surgery; * The time from the onset of aSAH symptoms to admission ≤ 72 hours; ⑥ The subject himself or the guardian of the subject knew and voluntarily signed the informed consent form. Exclusion Criteria: * Non aneurysmal subarachnoid hemorrhage; * Cognitive dysfunction existed before onset; * Patients with angina pectoris, bronchial asthma, mechanical intestinal obstruction, liver and kidney insufficiency, and urinary tract obstruction; * Complicated with other nervous system diseases, including nervous system degenerative diseases (Alzheimer's disease, Parkinson's disease, Lewy body dementia, frontotemporal dementia, etc.), neuromyelitis optica, epilepsy, central nervous system infection (such as AIDS, syphilis, etc.), brain traumatic dementia, etc; * Psychotic patients, according to DSM-IV-TR standards, including schizophrenia or other mental diseases, bipolar disorder, major depression or delirium; * Other cholinesterase inhibitor drugs are being used; ⑦ There are uncorrectable visual and auditory disorders, and neuropsychological tests and scales cannot be completed; * Have unstable or serious heart, lung, liver, kidney and hematopoietic system diseases; * Pregnant or lactating women and women of childbearing age without reliable contraception, and there is no evidence of negative pregnancy; ⑩ Patients who cannot be followed up as required during the study period; ⑪ Those who are allergic to the test drug; ⑫ Those who have participated in other clinical trials in recent 3 months; ⑬ Patients who are not suitable to participate in the clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aneurysmal subarachnoid hemorrhage are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two salts, one goal: which brain swelling treatment works best?
- Can a Nerve-Blocking drug stop the worst headaches after a brain bleed?
- Blood clot markers may forecast stroke outcomes
- Can a blood pressure cuff shield the brain after a severe stroke?
- Can a gentle ear zap calm the Brain's overactive 'Fight or Flight' response?
- Spinal zap may stop deadly brain artery spasms after aneurysm